Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-10-07
Schrödinger, Inc.
Schrödinger sells physics-based molecular discovery software and uses the same computational stack in partnered and proprietary drug discovery programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A credible path to a larger discovery layer
The upside case is a bigger share of discovery workflow spend, not a single miracle asset. If hosted delivery and AI modules deepen account economics, the company can outgrow its current niche despite a valuation that already expects real progress.

Analysis

Thesis
Over five years, Schrödinger can grow from a specialist modeling vendor into a higher-value discovery workflow layer: hosted delivery, embedded team workflows, and AI-assisted modules should expand wallet share inside major pharma accounts, while collaborations and royalties add upside without requiring balance-sheet-heavy lab buildout.
Last Economy Alignment
Cheaper cognition increases the amount of drug discovery work done in software, and Schrödinger owns a validated workflow surface. The cap is that value capture is still partly seat-driven and large pharma keeps bargaining power.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
This is a solid 2-5x setup, not a moonshot. The upside comes from deeper spend per large account rather than winning the whole market: hosted contracts improve quality, AI modules widen the user base beyond expert modelers, and collaborations preserve optionality. The stock already discounts some of this, so I assume multiple compression versus today and still get attractive upside if revenue compounds materially.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is economic capture, not scientific relevance. Schrödinger is likely to stay useful, but returns disappoint if AI boosts customer productivity without lifting Schrödinger’s share of the wallet, if top-account concentration keeps renewals lumpy, or if hosted and agentic products improve activity more than monetization.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They sit inside pharma discovery workflows where project data, simulations, and team decisions accumulate, so more AI use can make the software more valuable. The risk is that if agents shrink paid seats or customers keep orchestration in-house, Schrödinger stays important but captures too little of the gain.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.43
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case